KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Gross Margin (2019 - 2025)

Historic Gross Margin for Alnylam Pharmaceuticals (ALNY) over the last 7 years, with Q4 2025 value amounting to 75.6%.

  • Alnylam Pharmaceuticals' Gross Margin fell 71000.0% to 75.6% in Q4 2025 from the same period last year, while for Dec 2025 it was 78.5%, marking a year-over-year decrease of 78700.0%. This contributed to the annual value of 81.77% for FY2025, which is 46000.0% down from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Gross Margin stood at 75.6%, which was down 71000.0% from 84.21% recorded in Q3 2025.
  • Alnylam Pharmaceuticals' Gross Margin's 5-year high stood at 89.8% during Q2 2024, with a 5-year trough of 133.94% in Q1 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' median Gross Margin value was 85.61% (recorded in 2021), while the average stood at 74.03%.
  • Per our database at Business Quant, Alnylam Pharmaceuticals' Gross Margin skyrocketed by 134400bps in 2024 and then crashed by -2229000bps in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Gross Margin stood at 86.99% in 2021, then dropped by -1bps to 86.22% in 2022, then decreased by -3bps to 83.63% in 2023, then dropped by -1bps to 82.69% in 2024, then fell by -9bps to 75.6% in 2025.
  • Its Gross Margin was 75.6% in Q4 2025, compared to 84.21% in Q3 2025 and 81.64% in Q2 2025.